Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Exonuclease 3'-5' domain-containing 1 (EXD1) is a protein in humans with predicted 3'-5' exonuclease activity, meaning it specifically removes nucleotides from the 3' end of nucleic acids[7]. Studies indicate EXD1 interacts with proteins involved in the biogenesis of PIWI-interacting RNAs (piRNAs), contributing to RNA processing pathways that are crucial for genome defense in germ cells[7]. While related 3'-5' exonucleases in the same structural family function in nucleic acid proofreading and repair, EXD1 itself is mainly implicated in RNA metabolism rather than direct roles in DNA repair or recognized disease processes[7]. There is no evidence indicating EXD1 is a direct therapeutic target or is associated with drugs or clinical biomarkers at this time. Key points: - **Exonuclease 3'-5' domain-containing 1** (EXD1) possesses a characteristic 3'-to-5' exonuclease domain, placing it in the DEDDh/DnaQ superfamily of exonucleases[7]. - EXD1 is functionally distinct from related enzymes such as TREX1 ("Three prime repair exonuclease 1"), which is heavily involved in DNA repair and immune disease[1][9]. - EXD1 is not currently regarded as a primary drug target or disease biomarker. - The best characterized biological role of EXD1 is in facilitating piRNA precursor processing in the germline through its exonuclease activity and partnership with the protein TDRD12[7]. If more information on the molecular details, interacting proteins, or evolutionary context is required, refer to the EXD1 entry in NCBI Gene (ID: 161829), and emerging literature on piRNA pathway components[7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Exonuclease 3'-5' domain-containing 1 (EXD1).